| Characteristics . | Current Study . | |
|---|---|---|
| . | (n = 165) . | |
| . | No. of Patients . | % . |
| Enrollment by site | ||
| UCLA | 162 | 98.2 |
| KPLA | 3 | 1.8 |
| Age, years | ||
| Median | 60.9 | |
| Range | 22.1-84.3 | |
| <50 | 35 | 21.2 |
| ≥50 | 130 | 78.8 |
| Gender | ||
| Male | 99 | 60.0 |
| Female | 66 | 40.0 |
| Karnofsky Performance Status | ||
| 100 | 4 | 2.4 |
| 90 | 83 | 50.3 |
| 80 | 51 | 30.9 |
| 70 | 17 | 10.3 |
| ≤60 | 10 | 6.1 |
| Extent of Surgery | ||
| Biopsy | 15 | 9.1 |
| Subtotal resection | 62 | 37.6 |
| Gross total resection | 88 | 53.3 |
| Upfront Treatment | ||
| TMZ+Radiation | 160 | 97.0 |
| TMZ | 5 | 3.0 |
| Additional upfront treatmentsa | 65 | 39.4 |
| Recurrent treatment | ||
| Progressed | 115 | 69.7 |
| Received treatment post-progression | 103 | 62.4 |
| Deaths | 86 | 52.1 |
| Characteristics . | Current Study . | |
|---|---|---|
| . | (n = 165) . | |
| . | No. of Patients . | % . |
| Enrollment by site | ||
| UCLA | 162 | 98.2 |
| KPLA | 3 | 1.8 |
| Age, years | ||
| Median | 60.9 | |
| Range | 22.1-84.3 | |
| <50 | 35 | 21.2 |
| ≥50 | 130 | 78.8 |
| Gender | ||
| Male | 99 | 60.0 |
| Female | 66 | 40.0 |
| Karnofsky Performance Status | ||
| 100 | 4 | 2.4 |
| 90 | 83 | 50.3 |
| 80 | 51 | 30.9 |
| 70 | 17 | 10.3 |
| ≤60 | 10 | 6.1 |
| Extent of Surgery | ||
| Biopsy | 15 | 9.1 |
| Subtotal resection | 62 | 37.6 |
| Gross total resection | 88 | 53.3 |
| Upfront Treatment | ||
| TMZ+Radiation | 160 | 97.0 |
| TMZ | 5 | 3.0 |
| Additional upfront treatmentsa | 65 | 39.4 |
| Recurrent treatment | ||
| Progressed | 115 | 69.7 |
| Received treatment post-progression | 103 | 62.4 |
| Deaths | 86 | 52.1 |
Abbreviations: KPLA, Kaiser Permanente Los Angeles; TMZ, temozolomide; UCLA, University of California Los Angeles.
aNo patients received bevacizumab.
| Characteristics . | Current Study . | |
|---|---|---|
| . | (n = 165) . | |
| . | No. of Patients . | % . |
| Enrollment by site | ||
| UCLA | 162 | 98.2 |
| KPLA | 3 | 1.8 |
| Age, years | ||
| Median | 60.9 | |
| Range | 22.1-84.3 | |
| <50 | 35 | 21.2 |
| ≥50 | 130 | 78.8 |
| Gender | ||
| Male | 99 | 60.0 |
| Female | 66 | 40.0 |
| Karnofsky Performance Status | ||
| 100 | 4 | 2.4 |
| 90 | 83 | 50.3 |
| 80 | 51 | 30.9 |
| 70 | 17 | 10.3 |
| ≤60 | 10 | 6.1 |
| Extent of Surgery | ||
| Biopsy | 15 | 9.1 |
| Subtotal resection | 62 | 37.6 |
| Gross total resection | 88 | 53.3 |
| Upfront Treatment | ||
| TMZ+Radiation | 160 | 97.0 |
| TMZ | 5 | 3.0 |
| Additional upfront treatmentsa | 65 | 39.4 |
| Recurrent treatment | ||
| Progressed | 115 | 69.7 |
| Received treatment post-progression | 103 | 62.4 |
| Deaths | 86 | 52.1 |
| Characteristics . | Current Study . | |
|---|---|---|
| . | (n = 165) . | |
| . | No. of Patients . | % . |
| Enrollment by site | ||
| UCLA | 162 | 98.2 |
| KPLA | 3 | 1.8 |
| Age, years | ||
| Median | 60.9 | |
| Range | 22.1-84.3 | |
| <50 | 35 | 21.2 |
| ≥50 | 130 | 78.8 |
| Gender | ||
| Male | 99 | 60.0 |
| Female | 66 | 40.0 |
| Karnofsky Performance Status | ||
| 100 | 4 | 2.4 |
| 90 | 83 | 50.3 |
| 80 | 51 | 30.9 |
| 70 | 17 | 10.3 |
| ≤60 | 10 | 6.1 |
| Extent of Surgery | ||
| Biopsy | 15 | 9.1 |
| Subtotal resection | 62 | 37.6 |
| Gross total resection | 88 | 53.3 |
| Upfront Treatment | ||
| TMZ+Radiation | 160 | 97.0 |
| TMZ | 5 | 3.0 |
| Additional upfront treatmentsa | 65 | 39.4 |
| Recurrent treatment | ||
| Progressed | 115 | 69.7 |
| Received treatment post-progression | 103 | 62.4 |
| Deaths | 86 | 52.1 |
Abbreviations: KPLA, Kaiser Permanente Los Angeles; TMZ, temozolomide; UCLA, University of California Los Angeles.
aNo patients received bevacizumab.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
